Ripretinib is an orally bioavailable KIT/PDGFR inhibitor with antitumor effect. It binds to both wild-type and mutant forms of KIT and PDGFRa at their switch pocket binding site.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | PDGFR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye